Tonogenchoncel-L - Kolon TissueGene

Drug Profile

Tonogenchoncel-L - Kolon TissueGene

Alternative Names: Invossa K Inj.; Invossa K Injection; INVOSSA-K inj; TG C; TGF-beta-1 gene therapy - Kolon TissueGene; TissueGene-C; TissueGene-C(S); Transforming growth factor-beta-1 gene therapy - Kolon TissueGene

Latest Information Update: 12 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TissueGene
  • Developer Kolon Life Science; Kolon TissueGene
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Chondrocytes-replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 06 Jul 2018 USFDA lifts clinical hold on the pivotal phase III trial in Osteoarthiritis in USA
  • 26 Jun 2018 Mundipharma granted market license for tonogenchoncel-L in Saudi Arabia and United Arab Emirates
  • 26 Jun 2018 Tonogenchoncel-L market-licensed to Kolon Life Science in Saudi Arabia and United Arab Emirates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top